Skip to main content
Caplight Logo









Encellin

Encellin

Private
San Francisco, CaliforniaHealthcare & Life Scienceshttps://www.encellin.com/

Last Round

Series A

Dec 13, 2023

Est. Valuation

$2.14M

Total Funding Raised

$15.95M

Company Overview

Encellin is a biotechnology company that develops an innovative thin-film cell encapsulation device for cell-based therapeutics to treat type 1 diabetes and other endocrine disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Medical Devices, Clinical Trials, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

cell therapyencapsulated cell replacement therapyENCRTliving medicinetype 1 diabetesimplantable medical devicecell encapsulationbiocompatible pouchendocrine disordersbio-implantislet transplantationbiotech startupregenerative medicineclinical stage biotechhypoglycemia treatment

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Encellin Comparables

Compare Encellin with similar companies based on industry and business-model similarity.

Encellin comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Seraxis
86%
Sernova Biotherapeutics Inc.
83%
Betalin Therapeutics
82%

Encellin Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series ADec 13, 2023
SeedAug 5, 2021
AcceleratorAug 20, 2019

Key People

Founding team and executive leadership

Crystal Nyitray

CEO & Founder

Founding Team

Grace Wei

COO

Executive Team

Encellin Investors

Notable investors and investment history

Encellin investors
InvestorRounds
Khosla VenturesSeed, Series A
Y CombinatorSeed, Series A, Accelerator
SV Latam CapitalSeed
Sand Hill AngelsSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Dec 13, 2023

    $10M round led by Khosla Ventures

  • Aug 5, 2021

    $6M round led by Khosla Ventures and SV Latam Capital.

Recent news

Latest coverage and updates

  • partners_withSep 22, 2026

    Encellin partnered with BreakthroughT1D on Sep 22nd '26.

Encellin Filings

Explore SEC and related filing metadata, where available.

Encellin filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Encellin's valuation, stock price, and market status.

Is Encellin a public or private company?

Encellin is a private company.

What is the current stock price of Encellin?

Encellin is a private company with no public stock price. No recent secondary market data is available.

How much is Encellin worth (valuation)?

Valuation information for Encellin is not publicly available.

Can I buy Encellin stock?

Encellin shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Encellin's last funding round?

Encellin's most recent funding round was Series A on December 13, 2023.

Who are the main investors in Encellin?

Key investors in Encellin include Khosla Ventures.

Will Encellin IPO soon?

No public IPO plans have been announced for Encellin.

How can I track Encellin secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Encellin's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSan Francisco, California
Employee Range7
Year Founded2015
Last FundingDec 13, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?